You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
|
|---|---|
| Published in |
Journal of Translational Medicine, February 2012
|
| DOI | 10.1186/1479-5876-10-28 |
| Pubmed ID | |
| Authors |
Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada, H Kim Lyerly |
| Abstract |
Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease. HER2-based vaccines induce polyclonal antibody responses against HER2 that demonstrate enhanced anti-tumor activity when combined with lapatinib in murine models. We wished to test the clinical safety, immunogenicity, and activity of a HER2-based cancer vaccine, when combined with lapatinib. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Germany | 1 | 1% |
| Unknown | 78 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 23% |
| Student > Master | 9 | 11% |
| Student > Ph. D. Student | 7 | 9% |
| Student > Bachelor | 7 | 9% |
| Student > Postgraduate | 6 | 8% |
| Other | 12 | 15% |
| Unknown | 21 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 23% |
| Agricultural and Biological Sciences | 12 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
| Immunology and Microbiology | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Other | 7 | 9% |
| Unknown | 23 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2012.
All research outputs
#18,304,874
of 22,663,150 outputs
Outputs from Journal of Translational Medicine
#2,923
of 3,954 outputs
Outputs of similar age
#197,651
of 248,330 outputs
Outputs of similar age from Journal of Translational Medicine
#38
of 52 outputs
Altmetric has tracked 22,663,150 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,954 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,330 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.